PCa has shown limited response to immunotherapy because of its cold tumor environment.348 Notably, CDK4/6 inhibitors have been shown to increase the tumor immune response and TILs,362,363 which supports the potential synergistic effects of CDK4/6 inhibitors and ICIs. Here, CDK4 is linked to neoplasm.